By Michael Erman and Christy Santhosh
Aug 4 (Reuters) - Merck reported higher-than-expected second-quarter sales on Tuesday and raised its full-year revenue forecast on the strength of its top-selling cancer treatment Keytruda.
The U.S. drugmaker reported quarterly revenue of $16.61 billion, up 5% from a year earlier and above ******* ysts' average estimate of $16.36 billion, according to LSEG data.
Merck reported a loss for the quarter due to a $5.7 billion charge from its acquisition of cancer drug developer Terns Pharmaceuticals.
The company's reported loss in the quarter was 13 cents per share, including the $2.31 per share charge from the deal. ******* ysts had expected a larger adjusted loss per share of 27 cents, and Merck shares rose 0.6% to $128.54 in early trading.
#quarter #billion
Aug 4 (Reuters) - Merck reported higher-than-expected second-quarter sales on Tuesday and raised its full-year revenue forecast on the strength of its top-selling cancer treatment Keytruda.
The U.S. drugmaker reported quarterly revenue of $16.61 billion, up 5% from a year earlier and above ******* ysts' average estimate of $16.36 billion, according to LSEG data.
Merck reported a loss for the quarter due to a $5.7 billion charge from its acquisition of cancer drug developer Terns Pharmaceuticals.
The company's reported loss in the quarter was 13 cents per share, including the $2.31 per share charge from the deal. ******* ysts had expected a larger adjusted loss per share of 27 cents, and Merck shares rose 0.6% to $128.54 in early trading.
#quarter #billion
10 days ago
